Abstract
Lung cancer is one of the leading causes of cancer-related mortality worldwide. This article explores lung cancer from an academic perspective, focusing on risk factors, molecular mechanisms, diagnostic approaches, and emerging treatment strategies. Special attention is given to the role of smoking, genetic predisposition, and environmental factors. The article emphasizes the importance of biomarkers in early diagnosis and treatment planning, as well as the potential of nanotechnology for targeted therapy. Psychosocial aspects are also briefly discussed.
According to available data, lung cancer represents 12.7% of newly diagnosed cancer cases in Azerbaijan and 17.3% of cancer-related deaths, highlighting its significance and the importance of early detection.
Introduction
From a public health perspective, lung cancer remains a major global concern. One of the key challenges is late diagnosis, which negatively impacts survival rates. Lung cancer affects both men and women, with men showing slightly higher incidence rates, likely due to differential exposure to risk factors such as tobacco use. Early detection has improved thanks to imaging techniques like radiography and computed tomography. In addition, molecular biomarkers have become essential tools in guiding treatment strategies.
Types of Lung Cancer
Lung cancer originates from epithelial cells of the respiratory tract and is broadly categorized into two types:
• Non-Small Cell Lung Cancer (NSCLC) (80–85%)
• Adenocarcinoma
• Squamous cell carcinoma
• Large cell carcinoma
• Small Cell Lung Cancer (SCLC) (15–20%)
• More aggressive, tends to spread rapidly, and often diagnosed at advanced stages
Causes and Risk Factors
Based on academic literature, main risk factors for lung cancer include:
• Smoking and second-hand smoke exposure
• Air pollution
• Occupational hazards (e.g., radon, heavy metals)
• Previous radiation exposure
• Chronic lung diseases
• Genetic susceptibility
Molecular Pathogenesis and Biomarkers
Genetic mutations play a significant role in lung cancer development. Key molecular biomarkers include:
• EGFR
• ALK
• ROS1
• BRAF
• MET
• TP53
These biomarkers are important in research and can help guide the development of targeted therapies, although their clinical use requires professional oversight.
Treatment Approaches
Traditional methods:
• Surgical interventions
• Chemotherapy
• Radiotherapy
Modern and personalized approaches:
• Targeted therapy: Directed at specific genetic alterations, potentially improving treatment precision
• Immunotherapy: Strategies that support the immune system in recognizing cancer cells
• Gene therapy and CAR-T therapy: Experimental approaches under investigation in research settings
Nanotechnology in Lung Cancer
Nanotechnology is an emerging research field in oncology. It allows for potentially more targeted drug delivery and may reduce effects on healthy tissues. Academic studies report several advantages:
• Targeted drug delivery to tumor cells
• Improved stability and distribution of therapeutic agents
• Controlled release over time
However, limitations include:
• Challenges in precise targeting
• Potential toxicity
• High production costs
• Limited clinical application currently
Despite these challenges, nanotechnology remains a promising area for future research in lung cancer therapy.
Psychosocial Aspects
Lung cancer can have psychological effects, including anxiety and depression. Research suggests that psychosocial support, including counseling and family engagement, may improve patient wellbeing and treatment adherence.
Conclusion
Lung cancer continues to pose a global health challenge. Advances in molecular biology, biomarker research, and nanotechnology offer promising avenues for early detection and personalized treatment. Continued research and access to modern therapies are essential to further improve outcomes.